Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease

被引:61
作者
Chue, Colin D. [1 ,2 ]
Edwards, Nicola C. [1 ,2 ]
Davis, Laura J. [2 ,3 ]
Steeds, Richard P. [1 ,2 ]
Townend, Jonathan N. [1 ,2 ]
Ferro, Charles J. [2 ]
机构
[1] Queen Elizabeth Hosp, Dept Cardiol, Birmingham B15 2TH, W Midlands, England
[2] Univ Birmingham, Birmingham, W Midlands, England
[3] Queen Elizabeth Hosp, Dept Neurol, Birmingham B15 2TH, W Midlands, England
关键词
arterial stiffness; phosphate; progression of chronic kidney disease; pulse wave velocity; ARTERIAL STIFFNESS; SEVELAMER HYDROCHLORIDE; AUGMENTATION INDEX; MINERAL METABOLISM; MORTALITY RISK; PROGRESSION; PRESSURE; REPRODUCIBILITY; HYPERTENSION; ASSOCIATION;
D O I
10.1093/ndt/gfq787
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The rate of decline in kidney function is a powerful predictor of cardiovascular risk in patients with chronic kidney disease (CKD). Serum phosphate and increased arterial stiffness are associated with elevated cardiovascular risk in CKD and the general population. We sought to determine whether serum phosphate and markers of arterial stiffness predict progression of renal dysfunction in patients with early CKD. Methods. Two hundred and twenty-five patients with Stage II-IV CKD were prospectively followed up at University Hospital Birmingham. Serum phosphate was measured at baseline and arterial stiffness was determined through measurement of aortic pulse wave velocity (PWV) and augmentation index (AIx). Progression of renal dysfunction was defined as the slope of estimated glomerular filtration rate (eGFR) against time. We determined the associations between possible predictors and rate of progression and also examined a combined end point of start of dialysis or >= 25% decline in eGFR. Results. Mean baseline eGFR was 43 +/- 19 mL/min/1.73 m(2) and serum phosphate 1.22 +/- 0.27 mmol/L. Median follow-up was 924 days. Serum phosphate independently predicted a greater decline in eGFR; a 1 mmol/L increment in serum phosphate was associated with a 0.34 mL/min/month steeper decline (P = 0.02). Brachial and aortic systolic pressure independently predicted the rate of renal function decline but aortic PWV and AIx had no significant influence. Forty-one patients (18%) reached the combined end point; serum phosphate was significantly higher in this group (1.32 +/- 0.36 versus 1.19 +/- 0.24 mmol/L, P = 0.04) and was an independent predictor for the combined end point. Conclusions. Serum phosphate independently predicts decline in renal function in early CKD. Further studies are required to determine the mechanisms involved and to investigate the potential benefits of phosphate lowering on preserving kidney function.
引用
收藏
页码:2576 / U177
页数:7
相关论文
共 44 条
[1]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[2]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[3]   Arterial stiffness in chronic kidney disease: causes and consequences [J].
Chue, Colin D. ;
Townend, Jonathan N. ;
Steeds, Richard P. ;
Ferro, Charles J. .
HEART, 2010, 96 (11) :817-823
[4]   Elevated Serum Phosphate Predicts Mortality in Renal Transplant Recipients [J].
Connolly, Grainne M. ;
Cunningham, Ronan ;
McNamee, Peter T. ;
Young, Ian S. ;
Maxwell, Alexander P. .
TRANSPLANTATION, 2009, 87 (07) :1040-1044
[5]   Promoting scientific collaboration and education in cardiovascular-renal medicine [J].
Covic, Adrian ;
Fliser, Danilo ;
Goldsmith, David ;
Lindholm, Bengt ;
London, Gerard ;
Martinez, Alberto ;
Suleymanlar, Gultekin ;
Wiecek, Andrzej ;
Zoccali, Carmine .
CLINICAL KIDNEY JOURNAL, 2009, 2 (06) :522-525
[6]   Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia [J].
Cozzolino, M ;
Staniforth, ME ;
Liapis, H ;
Finch, J ;
Burke, SK ;
Dusso, AS ;
Slatopolsky, E .
KIDNEY INTERNATIONAL, 2003, 64 (05) :1653-1661
[7]   Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community [J].
Dhingra, Ravi ;
Sullivan, Lisa M. ;
Fox, Caroline S. ;
Wang, Thomas J. ;
D'Agostino, Ralph B. ;
Gaziano, J. Michael ;
Vasan, Ramachandran S. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (09) :879-885
[8]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[9]   Is lowering phosphate exposure the key to preventing arterial stiffening with age? [J].
Ferro, C. J. ;
Chue, C. D. ;
Steeds, R. P. ;
Townend, J. N. .
HEART, 2009, 95 (21) :1770-1772
[10]   Central aortic pressure augmentation in stable renal transplant recipients [J].
Ferro, CJ ;
Savage, T ;
Pinder, SJ ;
Tomson, CRV .
KIDNEY INTERNATIONAL, 2002, 62 (01) :166-171